EU sourced Avastin®

BIOLOGICAL2 trials

Sponsors

Samsung Bioepis Co., Ltd., Cipla BioTec Pvt. Ltd.

Conditions

Healthy

Phase 1

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

CompletedNCT02453672

Samsung Bioepis Co., Ltd.Healthy

Start: 2015-04-30End: 2015-09-30Updated: 2019-06-03

PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)

Cipla BioTec Pvt. Ltd.Healthy

Start: 2016-06-30End: 2016-12-31Target: 150Updated: 2016-09-19

Related Papers

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.

2020-09-1913 citations